Sun Pharma Share Price in Focus; Joins S&P Global Sustainability Yearbook 2025

Sun Pharmaceutical Industries Limited has been gaining attention on Wednesday. On February 19, 2025, Sun Pharma share price opened at ₹1,665.10, down from its previous close of ₹1,701.60. At 11:35 AM, the share price of Sun Pharma was trading at ₹1,695.75, down by 0.34% on the NSE. The stock price touched its day’s low so far at ₹1,647.10.

Sun Pharma Recognised in S&P Global Sustainability Yearbook 2025

Recently, on February 17, 2025, Sun Pharmaceutical Industries Limited announced its inclusion in the S&P Global Sustainability Yearbook 2025, ranking among the top 5% of pharmaceutical companies globally. This recognition highlights Sun Pharma’s strong Environmental, Social, and Governance (ESG) practices and sustainability-focused initiatives.

The S&P Global Corporate Sustainability Assessment (CSA) 2024 evaluated 7,690 companies worldwide, with only 780 companies qualifying for the yearbook. Sun Pharma’s inclusion underscores its commitment to corporate responsibility, sustainable operations, and ethical governance.

This achievement reflects Sun Pharma’s ongoing efforts to integrate sustainability into its business practices, reinforcing its position as a responsible global pharmaceutical leader. The company continues to implement initiatives that drive environmental stewardship, social well-being, and governance excellence, ensuring long-term value for stakeholders.

Commenting on this development, the Chairman and Managing Director of the company, Dilip Shanghvi, said, “We continue to focus on delivering sustainable outcomes for all our stakeholders. Sustainability is an integral part of our way of doing business and we remain steadfast in our commitment to align our strategy with universal ESG principles and to undertake the requisite steps for further advancing societal goals.”

Conclusion

Sun Pharma’s inclusion in the S&P Global Sustainability Yearbook 2025 highlights its strong ESG commitment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.